Company Analysis

Fate Therapeutics, Inc. (FATE)

Nasdaq: FATE · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2008
Grade4.1
◀ Past 5.1● Present 4.5▶ Future 3.1
1 est.

Who runs Fate Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Valamehr Bahram
President and CEO. First filing Aug 2018, latest Aug 5, 2026, 21 filings in all.
Officers reporting now
4
of 14 people with a filing in the last fifteen months
Directors reporting now
10
29 people on the record since 2013
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Adawi KamalChief Financial OfficerOct 2025Nov 4, 20261 · $0.00
Valamehr BahramPresident and CEOAug 2018Aug 5, 20263 · $200,000
Tahl CindyChief Legal and Compliance OfficerOct 2015Aug 5, 20263 · $200,000
Green Jeremyofficer and directorDec 2017Jun 15, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Abernethy MattdirectorMay 2025Jun 15, 2026none
Agarwal ShefalidirectorJul 2019Jun 15, 2026none
Epstein Robert SdirectorMar 2014Jun 15, 2026none
Hamill LauradirectorJun 2026Jun 15, 2026none
Jooss KarindirectorMar 2019Jun 15, 2026none
Lee Michael StewartdirectorAug 2018Jun 15, 2026none
Rastetter William HdirectorSep 2013Jun 15, 2026none
Redmile Group, LLCManaging MemberDec 2017Jun 15, 2026none
Xu YuandirectorAug 2021Jun 15, 2026none
Redco II Master Fund, L.P.directorJul 2025Apr 23, 2026none
Earlier names on the record15, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton FATE · research, not advice